Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.65+2.70%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ENTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -64.4% |
| Our one-year growth estimate | diamond | -5.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 59.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ENTA — CEO transition
Dated 2026-10-28
CEO — Jay R. Luly: The CEO is retiring in an orderly manner with a strategic advisor transition and a search for a successor initiated, rather than a sudden loss of leadership.
Why it matters: An IND filing would clear a step toward human testing of this oral STAT6 drug. A delay would push back the program.
Supportive ifEnanta files the EPS-3903 IND with the FDA by December 31, 2026.
Worry ifEnanta says the IND filing moved beyond 2026, or reports that it has not filed by year-end.
Why it matters: The first data will show how the KIT drug acts in people. Safety and serum tryptase results are key early checks.
Watch forQ4 data show no dose-limiting safety issue. Serum tryptase falls after dosing.
Also watch forThe trial reports a safety issue that limits the dose, or serum tryptase does not drop after dosing.
Why it matters: The board has begun a search as Jay Luly plans to retire by February 1, 2027. A clear handoff can help keep the pipeline plan steady.
Watch forEnanta names a successor by February 1, 2027, and confirms Luly will advise through the end of 2027.
Also watch forEnanta has not named a successor by February 1, 2027, or reports a change to the planned handoff.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$228 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $435 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,846 loss on $10,000 · 38.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.